Phaseline

Companies › Eikon Therapeutics

Eikon Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 3 Phase 2, 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EIK1001
Toll-like receptor 7/8 (TLR 7/8) agonist
TLR7, TLR8Phase 2NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous)Dec 2026
IMP1734
PARP1 selective inhibitor
PARP1Phase 1Advanced Solid TumorJun 2027
EIK1004 (IMP1707)
PARP1 selective inhibitor
PARP1Phase 1Advanced Solid TumorsDec 2028
EIK1005
Werner helicase inhibitor
WRNPhase 1Advanced Solid TumorsMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06246110EIK1001Phase 2NSCLCOncologyDec 2026
NCT06253130IMP1734Phase 1Advanced Solid TumorOncologyJun 2027
NCT06907043EIK1004 (IMP1707)Phase 1Advanced Solid TumorsOncologyDec 2028
NCT07262619EIK1005Phase 1Advanced Solid TumorsOncologyMar 2029
NCT06697301EIK1001Phase 2Advanced MelanomaOncologyDec 2035
NCT07365319EIK1001Phase 2Non Small Cell Lung Cancer (Squamous or Non Squamous)OncologyDec 2035

From the company's SEC filings

Cash and short-term investments of $531m on 2026-06-30; operating cash outflow about $314m a year; runway about 20 months at that burn, to Mar 2028; 1 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PARP1 (2) TLR7 (1) TLR8 (1) WRN (1)

Companies with the same targets

AstraZeneca Merck KGaA United Immunity Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune Haisco Pharmaceutical Group Hangzhou SynRx Therapeutics Biomedical Technology

Companies built like this

ALX Oncology Kura Oncology Vividion Therapeutics Cellectar Biosciences Acrivon Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.